Medication Assistance Programs Mitigating Financial Burden For Patients Receiving Bispecific Therapy

EP: 1.Conditions for Administering Bispecific Therapy

EP: 2.Navigating Barriers Which Inhibit Optimal Use of Bispecifics

EP: 3.Key Decision Makers and Contributors Involved In Bispecific Administration

EP: 4.Pain Points In Bispecific Operationalization

EP: 5.Risk Evaluation and Mitigation Strategies [REMS] Program Considerations For Bispecific Therapy

EP: 6.Optimizing Bispecific Use Through EMR Utilization

EP: 7.Best Practices For Uptake and Use of Bispecific Therapy

EP: 8.Achieving Seamless Care Transitions With Patients Receiving Bispecific Therapy

EP: 9.Intro to Bispecific Therapy: Implementation Essentials for Novice Institutions

EP: 10.Key Elements In Monitoring for Potential Adverse Events with Bispecific Antibodies

EP: 11.Protocol For Urgent and Around-the-Clock Bispecific Care

EP: 12.Obstacles to Optimal Transitions of Care Between Academic and Community Settings When Utilizing Bispecific Antibodies

EP: 13.Managed Care Considerations Within Bispecific Landscape

EP: 14.Payor-Provider Collaboration Driving Optimal Bispecific Therapy Strategies

Now Viewing

EP: 15.Medication Assistance Programs Mitigating Financial Burden For Patients Receiving Bispecific Therapy

EP: 16.Bispecific Therapies: Current and Future Considerations

The following is a video synopsis/summary of a Peer Exchange involving Ryan Haumschild, PharmD, MS, MBA, CPEL; Kirollos Hanna, PharmD, BCPS, BCOP, FACCC; Sarah Rockwell, PharmD, BCOP; Melody Chang, RPh, MBA, BCOP; and Ryan Cain, PA-C.

Video synopsis is AI-generated and reviewed by AJMC editorial staff.